Ekso Bionics Holdings
Market Cap
US$40.3m
Last Updated
2019/09/23 00:27 UTC
Data Sources
Company Financials +
Executive Summary
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa.
Snowflake
Fundamentals
Mediocre balance sheet with limited growth.
Risks
- Ekso Bionics Holdings has significant price volatility in the past 3 months.
- Ekso Bionics Holdings is covered by less than 3 analysts.
Similar Companies
Share Price & News
How has Ekso Bionics Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-4.1%
EKSO
1.2%
US Medical Equipment
-0.6%
US Market
1 Year Return
-76.9%
EKSO
9.7%
US Medical Equipment
0.7%
US Market
EKSO underperformed the Medical Equipment industry which returned 9.9% over the past year.
EKSO underperformed the Market in United States of America which returned 0.7% over the past year.
Share holder returns
| EKSO | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.1% | 1.2% | -0.6% |
| 30 Day | -29.3% | 3.5% | 4.9% |
| 90 Day | -57.7% | 3.2% | 1.7% |
| 1 Year | -76.9%-76.9% | 10.6%9.7% | 3.0%0.7% |
| 3 Year | -85.1%-85.1% | 70.6%65.4% | 44.8%35.4% |
| 5 Year | -90.7%-90.7% | 139.4%112.2% | 62.0%44.3% |
Price Volatility Vs. Market
How volatile is Ekso Bionics Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
What Kind Of Shareholders Own Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?1 month ago | Simply Wall St
Is Ekso Bionics Holdings (NASDAQ:EKSO) Using Too Much Debt?2 months ago | Simply Wall St
Before You Buy Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), Consider Its VolatilityValuation
Is Ekso Bionics Holdings undervalued based on future cash flows and its price relative to the stock market?
7.45x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Ekso Bionics Holdings to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Ekso Bionics Holdings to establish if it is available at substantial discount.
Price Based on Earnings
Ekso Bionics Holdings is loss making, we can't compare its value to the US Medical Equipment industry average.
Ekso Bionics Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Ekso Bionics Holdings, we can't assess if its growth is good value.
Price Based on Value of Assets
Ekso Bionics Holdings is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Ekso Bionics Holdings expected to perform in the next 1 to 3 years based on estimates from 2 analysts?
8.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Ekso Bionics Holdings's revenue is expected to grow significantly at over 20% yearly.
Ekso Bionics Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
Ekso Bionics Holdings's revenue growth is expected to exceed the United States of America market average.
Unable to compare Ekso Bionics Holdings's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare Ekso Bionics Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Ekso Bionics Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Ekso Bionics Holdings performed over the past 5 years?
-9.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Ekso Bionics Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Ekso Bionics Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Ekso Bionics Holdings's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Ekso Bionics Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Ekso Bionics Holdings has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Ekso Bionics Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Ekso Bionics Holdings's financial position?
Financial Position Analysis
Ekso Bionics Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Ekso Bionics Holdings's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Ekso Bionics Holdings's level of debt (71.6%) compared to net worth is high (greater than 40%).
Ekso Bionics Holdings had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 5.7x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Ekso Bionics Holdings has less than a year of cash runway based on current free cash flow.
Ekso Bionics Holdings has less than a year of cash runway if free cash flow continues to reduce at historical rates of -8.1% each year.
Next Steps
Dividend
What is Ekso Bionics Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Ekso Bionics Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Ekso Bionics Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Ekso Bionics Holdings has not reported any payouts.
Unable to verify if Ekso Bionics Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Ekso Bionics Holdings has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Ekso Bionics Holdings's salary, the management and board of directors tenure and is there insider trading?
1.3yrs
Average management tenure
CEO
Jack Peurach (53yo)
1.5yrs
Tenure
US$4,367,123
Compensation
Mr. Jack Peurach has been President and Chief Executive Officer at Ekso Bionics Holdings, Inc. since March 9, 2018. Mr. Peurach served as an Executive Vice President of Products at SunPower Corporation sin ...
CEO Compensation Analysis
Jack's remuneration is higher than average for companies of similar size in United States of America.
Jack's compensation has increased whilst company is loss making.
Management Age and Tenure
1.3yrs
Average Tenure
55yo
Average Age
The average tenure for the Ekso Bionics Holdings management team is less than 2 years, this suggests a new team.
Board Age and Tenure
5.7yrs
Average Tenure
62yo
Average Age
The tenure for the Ekso Bionics Holdings board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 31,437 |
| Max Price | US$1.37 |
| Entity | Individual |
| Shares | 9,430 |
| Max Price | US$1.31 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Secretary |
| Shares | 10,292 |
| Max Price | US$1.37 |
Ownership Breakdown
Management Team
Jack Glenn (57yo)
CFO & Secretary
- Tenure: 1.1yrs
- Compensation: US$1.04m
Steven Sherman (73yo)
Executive Chairman
- Tenure: 5.7yrs
- Compensation: US$1.53m
Jack Peurach (53yo)
President
- Tenure: 1.5yrs
- Compensation: US$4.37m
Bill Shaw (45yo)
Chief Commercial Officer
- Tenure: 0.4yrs
Matthias Stief
Managing Director of Ekso Bionics Europe GmbH
- Tenure: 2.8yrs
Foon Lim Chwee
President of APAC
- Tenure: 1.7yrs
Board Members
Stanley Stern (62yo)
Independent Director
- Tenure: 4.8yrs
- Compensation: US$101.77k
Tom Schreck (61yo)
Director
- Tenure: 0.8yrs
- Compensation: US$46.44k
Steven Sherman (73yo)
Executive Chairman
- Tenure: 5.7yrs
- Compensation: US$1.53m
Marilyn Hamilton (70yo)
Independent Director
- Tenure: 5.7yrs
- Compensation: US$98.03k
Hans Keirstead
Member of Advisory Council
- Tenure: 0yrs
Jack Peurach (53yo)
President
- Tenure: 1.5yrs
- Compensation: US$4.37m
Nancy Byl
Member of Advisory Council
- Tenure: 0yrs
Tom Kelley
Member of Advisory Council
- Tenure: 0yrs
Kel Bergmann
Member of Advisory Council
- Tenure: 0yrs
Graham Creasey
Member of Advisory Council
- Tenure: 0yrs
Company Information
Ekso Bionics Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Ekso Bionics Holdings, Inc.
- Ticker: EKSO
- Exchange: NasdaqCM
- Founded: 2005
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$40.284m
- Shares outstanding: 74.92m
- Website: https://www.eksobionics.com
Number of Employees
Location
- Ekso Bionics Holdings, Inc.
- 1414 Harbour Way South
- Suite 1201
- Richmond
- California
- 94804
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EKSO | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jan 2014 |
| 230 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 2014 |
| 0IFR | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 2014 |
Biography
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/23 00:27 |
| End of Day Share Price | 2019/09/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.